Up to now, there are only two studies about the effect of TNF-α blockers in AS patients, and both of them suggested that treatment with TNF-α antagonism caused a significant decrease in depression-anxiety scores and disease activity and a significant increase in QOL, and this change in disease activity was not correlated with changes in depression and anxiety scores [27,136]. The gene discussed is TNF; the disease is depressive disorder.